Company intelligence / Profile preview

Yellow Jersey Therapeutics

Zug/Zürich, Switzerlandjnj.com ↗

Overview

Acquired by Johnson & Johnson for $1.25B in July/May2024[1][5][10]
NM26: First-in-class bispecific antibody targeting Th2 inflammation and pruritus pathways[1][4]
Phase-2 ready asset with global rights secured by J&J (Asia Pacific via Kaken partnership)[1][6]

1 asset

Phase 2

Kaken Pharmaceutical (Asia Pacific rights)HBM Healthcare Investments (investor)Numab Therapeutics (originator)

Beyond the preview

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Follow clinical development from trial design and recruitment through results.

Explore licensing agreements, acquisitions, and the assets behind each deal.

Trace financing activity and the investors behind a company’s development.

Compare peer pipelines by target, modality, and therapeutic area.

Explore technology platforms and the patent landscape around relevant assets.

Connect company news and source material to the questions you’re investigating.

See how Gosset can support your research on Yellow Jersey Therapeutics.